The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - Kidney Week 2023: Annual Meeting of the American Society of Nephrology

Complement in the kidney and beyond: Understanding pathophysiology and treatment outcomes in aHUS

Philadelphia, Pennsylvania / November 2–5, 2023

Philadelphia – Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) in which dysregulation of the complement cascade leads to microvascular thrombi, microangiopathic hemolytic anemia, thrombocytopenia,...

PRIORITY PRESS - 60th ERA Congress: European Renal Association (ERA)

A decade of improved outcomes in aHUS: insights on complement inhibition and special populations

In-person/virtual, Milan, Italy / June 15–18, 2023

Milan – Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) characterized by microangiopathic anemia with red blood cell fragmentation, thrombocytopenia, and acute kidney injury. Over the...

PRIORITY PRESS - Kidney Week 2022 – American Society of Nephrology (ASN)

Updates on aHUS: Latest Insights into Triggers, Diagnosis, and Management Outcomes

In-person/virtual, Orlando, Florida / November 3–6, 2022

In-person/Virtual – Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) that primarily affects the kidney but has a wide variability in its triggers and clinical presentation. In spite of its...

PRIORITY PRESS - Kidney Week 2021 (American Society of Nephrology)

Rare Kidney Disease in the Time of COVID: Update on Atypical Hemolytic Uremic Syndrome (aHUS)

Online / November 4–7, 2021

Online – Despite its rarity, atypical hemolytic uremic syndrome (aHUS) featured prominently in this year’s virtual Kidney Week – including the second reported case worldwide of aHUS due to COVID-19. Presenters explored the...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the 49th Annual Meeting of the European Association for the Study of the Liver (EASL)

New Direct-acting Antiviral Agents in the Treatment of Hepatitis C Genotype 1 Infection

London, UK / April 9-13, 2014

Guest Editor: Jordan J. Feld, MD, MPHToronto Centre for Liver DiseaseToronto Western HospitalFrancis Family Liver ClinicUniversity Health NetworkMcLauglin-Rotman Centre for Global HealthToronto,...

PRIORITY PRESS - Kidney Week - American Society of Nephrology (ASN)

Expanding Therapeutic Tools Encourage Individualized Therapy for ANCA Vasculitis

Atlanta, Georgia / November 5-10, 2013

Atlanta - A treatment algorithm is evolving for anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis based on disease severity. Although the therapeutic options remain limited, they have expanded, permitting treatment to be...

PRIORITY PRESS - Kidney Week - American Society of Nephrology (ASN)

Unpredictability of aHUS and Benefit of Early Therapy Supports High Index of Suspicion

Atlanta, Georgia / November 5-10, 2013

Atlanta - Atypical hemolytic uremic syndrome (aHUS) affects both children and adults, is characterized by systemic thrombotic microangiopathy, which can lead to stroke, heart attack, kidney failure, and death. Despite plasma...

PRIORITY PRESS - Annual General Meeting of the Canadian Society of Nephrology

Exploring B-cell Targeted Therapy in the Management of Glomerulonephritis

Montreal, Québec / April 24-28, 2013

Montreal - Treatment of glomerulonephritis has long been dependent on the use of steroids plus cytotoxic or antiproliferative drugs. With the success of therapeutic monoclonal agents in other autoimmune diseases, their use in...

MEDICAL FRONTIERS - 48th Annual Meeting of the European Association for the Study of the Liver

New Protease Inhibitor Data Support Large Leap in Hepatitis C Virus Control

Amsterdam, The Netherlands / April 24-28, 2013

Amsterdam - In the rapidly evolving field of hepatitis C virus (HCV), protease inhibitors (PIs) are poised to provide additional incremental increases to sustained virologic remission (SVR) rates in difficult cases. Since their...

PAGE 1 OF 7   1 2 3 4 5 6 7